Inpatient Rehabilitation Growth and Margin Expansion

Encompass Health Corporation is the largest owner and operator of freestanding inpatient rehabilitation hospitals in the United States, following the 2022 spin-off of its home health and hospice segment. The company provides intensive, physician-led rehabilitation to patients recovering from stroke, traumatic brain injury, spinal cord injury, neurological disorders, orthopedic conditions and other complex medical events.

How it makes money: Revenue is generated per discharge, with reimbursement from Medicare fee-for-service, Medicare Advantage, Medicaid and commercial insurers. Patients typically require a three-week stay with a minimum of three hours of therapy per day across physical, occupational and speech therapy, delivered by an interdisciplinary clinical team under the direction of a rehabilitation physician.

Customers and referral sources: The company's "customers" are effectively the payers, while its referral sources are acute-care hospitals, physicians, case managers and discharge planners. The concentration of referrals from acute-care hospitals makes discharge-planning relationships a critical competitive asset.

Scale: Encompass Health operates roughly 160 inpatient rehabilitation hospitals across approximately 40 states and Puerto Rico, with more than 40 additional hospitals under construction or in development. The company employs tens of thousands of people, principally nurses, therapists and support staff, and generates annual revenue in the range of $5 billion. With a market capitalization of $12.1B and 98.65M shares outstanding, it is the scale incumbent in a fragmented field of hospital-owned rehabilitation units and smaller regional operators.

Near-term (next 12–24 months):

• De novo openings: Hospitals currently under construction convert into revenue as they open and ramp, providing a predictable volume tailwind independent of same-store utilization.
• Bed additions at existing hospitals: Adding beds to mature campuses carries higher incremental margins than new construction because overhead is already in place.
• Payer mix improvement: Continued negotiation of Medicare Advantage rates toward fee-for-service parity and disciplined management of Medicaid exposure.
• Labor cost stabilization: Improving nursing and therapy labor markets reduce reliance on premium-priced contract labor, supporting margin expansion.

Medium-term (3–5 years):

• Demographic demand growth: The 65-plus cohort is the fastest-growing segment of the U.S. population, and rehabilitation utilization rises steeply with age.
• Site-of-service migration: Payers and physicians continue to shift complex rehabilitation volume away from skilled nursing facilities and toward freestanding inpatient rehabilitation hospitals, where outcomes are better documented.
• Pipeline maturation: The current development pipeline, if converted at historical rates, supports mid-single-digit to high-single-digit bed count growth for several years.
• Capital allocation: Free cash flow after maintenance capital and development spending supports modest deleveraging and potential shareholder returns, augmenting per-share earnings growth.

Historical figures are indicative estimates for illustrative modeling; the trailing EPS of $5.98 and share count of 98.65M are the live reported data points.

The financial trajectory is driven by three reinforcing factors. First, revenue growth in the high single digits comes from a combination of new hospital openings, same-store discharge growth and reimbursement rate increases. Second, adjusted EBITDA margin expansion of roughly 50 basis points per year reflects operating leverage on fixed hospital costs and a declining reliance on contract labor. Third, EPS grows faster than revenue because the share count is stable to modestly declining and interest expense grows slowly relative to EBITDA. The result is a low-beta compounding profile rather than a cyclical earnings story.

Market size: U.S. inpatient rehabilitation is a market of roughly $20 billion in annual spending, growing in the mid-single digits as the population ages and as site-of-service migration continues. Encompass Health holds an estimated 20–25% share of the freestanding inpatient rehabilitation hospital segment, making it the clear scale leader.

Competitive positioning: The company's advantages are (1) scale in purchasing, payer contracting and corporate overhead; (2) a repeatable de novo development playbook refined over decades; (3) clinical outcomes data that supports referral relationships; and (4) a national brand that helps recruit physicians and therapists. Its main competitive constraint is not rival operators but the reimbursement framework, which determines how much of the value created is captured by the company versus the payer.

Named comparables:

• Select Medical Holdings (SEM): Operates long-term acute care hospitals, inpatient rehabilitation hospitals and outpatient therapy clinics; the closest direct competitor in post-acute care.
• HCA Healthcare (HCA): Owns inpatient rehabilitation units within its acute-care hospitals and competes for the same referral flow.
• Tenet Healthcare (THC): Through its hospital network and ambulatory surgery and rehabilitation assets, competes for post-acute and outpatient rehabilitation volume.
• Acadia Healthcare (ACHC): A behavioral health operator with a comparable de novo growth model, useful as a valuation reference for capacity-led healthcare compounders.

Discounted cash flow: A DCF using a weighted average cost of capital of roughly 7.5–8.5% — supported by the 0.60 beta, moderate leverage and stable cash flows — and a terminal growth rate of 2.5–3.0% implies a fair value range in the low-to-mid $130s per share. The key sensitivities are the long-run EBITDA margin (each 100 basis points is worth roughly $10–12 per share) and the pace of de novo openings, which drive the mid-cycle growth rate. A more conservative scenario with flat margins and slower development yields a value closer to $110.

Comparable multiples:

Encompass Health's premium to hospital-centric peers reflects its higher growth rate, lower capital intensity relative to acute-care hospitals and cleaner pure-play exposure to post-acute rehabilitation. Relative to Acadia, the closest growth-model comparable, EHC trades at a modest premium on P/E but a similar EV/EBITDA, which we view as reasonable given its larger and more predictable development pipeline.

• Reimbursement policy risk: Changes to Medicare inpatient rehabilitation facility payment rules, the 60% compliance threshold or Medicare Advantage rate negotiation could compress revenue per discharge faster than costs can be adjusted.
• Labor cost inflation: Nursing and therapy wage pressure, including agency labor, is the largest controllable cost risk; sustained shortages would erode the margin expansion embedded in estimates.
• Development execution risk: De novo hospitals require certificate-of-need approvals, construction timelines and physician recruitment; delays push revenue out and raise per-project costs.
• Payer concentration and mix shift: A faster shift toward Medicare Advantage and Medicaid, which generally reimburse at lower rates than Medicare fee-for-service, would pressure margins.
• Regulatory and competitive encroachment: Acute-care hospital systems building their own rehabilitation units, and alternative payment models that redirect post-acute volume, could slow referral growth.